Myriad Genetics to sell prenatal testing business to Labcorp for $210 million
Myriad Genetics agreed on October 19, 2026 to sell its prenatal health testing business to Laboratory Corporation of America (Labcorp) for $210 million in cash, plus the value of the business's inventory at closing. The company says the sale is expected to be accretive to revenue growth and profitability and to strengthen its balance sheet, but the filing does not give Myriad's own revenue or profit figures for the business.
Key points
- Price is $210 million in cash plus inventory value at closing, under an Asset Purchase Agreement dated October 19, 2026.
- Labcorp expects the business to add approximately $160 million in revenue in year one and to be slightly accretive to its adjusted earnings in year one.
- Closing is subject to regulatory clearance and customary conditions and is expected by early 2027; Buyer may owe Myriad a $10,500,000 termination fee if regulatory clearances fail.
- Myriad plans to provide further commentary on the transaction and related organizational changes on its third quarter earnings call on November 4, 2026.
The filing
Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.